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The efficacy and safety of aminoglycosides given in combination with b-lactams for the
treatment of febrile neutropaenia in patients with acute leukaemia or bone marrow trans-
plantation was assessed using an evidence-based review of the literature with the aim to
formulate treatment guidelines. These recommendations have been developed by an
expert panel of the European Conference on Infections in Leukaemic patients (ECIL-1).
We also present results of a questionnaire on current treatment practice in Europe. The
expert panel concluded that b-lactam monotherapy is as efficacious as and less toxic than
b-lactam-aminoglycoside combination therapy as empirical therapy. The choice of b-lac-
tam should be based on local epidemiological data, antibiotic resistance patterns, recent
b-lactam use and available evidence. Combination therapy should be reserved for patients
presenting with severe sepsis or septic shock or for those with a high suspicion of resistant
Gram-negative infections, pending susceptibility testing and institution of appropriate b-
lactam monotherapy.
 2007 Elsevier Ltd. All rights reserved.1. Introduction
Early, broad-spectrum empirical antibiotic treatment for feb-
rile neutropaenic patients hasmarkedly reduced themortality
of Gram-negative infections.1,2 For about two decades, combi-
nations of an anti-pseudomonal b-lactam antibiotic with aner Ltd. All rights reserved
ollowing groups or organi
WP), Infectious Diseases
, Net (ELN) (EU Grant num
fax: +972 3 9376512.
aul).aminoglycoside have been a gold standard for empirical ther-
apy of suspected infections in febrile neutropaenic patients.3,4
The rationale for combination therapy included broad-spec-
trum coverage, possible synergistic activity against Gram-neg-
ative bacteria (especially Pseudomonas aeruginosa) and the
prevention of emergence of antibiotic resistance. Since the.
zations: Infectious Diseases Working Party of the European Blood
Group of the European Organization for Research and Treatment
ber: LSHC-CT-2004), and International Immunocompromised Host
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trials have shown that monotherapy with broad-spectrum
third- and fourth-generation cephalosporins (ceftazidime,
cefpirome and cefepime), carbapenems (imipenem-cilastatin,
meropenem) or anti-pseudomonal penicillins combined with
an inhibitor of b-lactamases (piperacillin-tazobactam) was as
efficacious as and less nephrotoxic or ototoxic than standard
b-lactam-aminoglycoside combinations.
Until a few years ago, the management of cancer patients
with febrile neutropaenia was fairly uniform. Recent ad-
vances in the treatment of cancer and management of che-
motherapy-related complications have led to the
recognition that all febrile neutropaenic patients are not at
the same risk of infectious complications. Several factors
can be used to classify patients into low or high risk catego-
ries.5,6 Assessing whether the patient belongs to a low risk
or high risk group is important; indeed, while low-risk pa-
tients may nowadays be safely treated with oral antibiotics,7
high-risk patients should continue to receive intravenous
broad-spectrum antibiotics. Patients with acute leukaemia,
who are the focus of the present guidelines, are generally
considered as high-risk patients.
With the advent of broad-spectrum and highly bacterici-
dal b-lactam antibiotics and the shift from Gram-negative ba-
cilli to Gram-positive cocci as the predominant cause of
infections in neutropaenic cancer patients in the late 1980s
and early 1990s,8 the need for using an aminoglycoside in
the empirical antibiotic regimen was a matter of considerable
debate. The objective of the present article was to review the
evidence supporting the use of aminoglycosides for manag-
ing bacterial infections in febrile neutropaenia. The literature
was reviewed with the aim to answer the following
questions:
(1) Isb-lactammonotherapyasefficacious asa combination
of a b-lactam plus an aminoglycoside for upfront empir-
ical therapy in high-risk febrile neutropaenic patients?
(2) Is a combination of a b-lactam plus an aminoglycoside
more nephrotoxic or ototoxic than b-lactam
monotherapy?
(3) Is there evidence that once-daily dosing of aminogly-
cosides is as efficacious as and potentially less toxic
than multiple-daily dosing in febrile neutropaenic
patients?
(4) Is there evidence supporting the empirical addition of
an aminoglycoside to patients initially treated with
monotherapy with persistent fever?
(5) Are there specific clinical conditions justifying the use
of an aminoglycoside as part of the empirical antibiotic
regimen?
(6) Does the use of b-lactam-aminoglycoside combinations
in neutropaenic patients prevent the emergence of bac-
terial resistance?2. Materials and methods
The Cochrane Library (September 2005) and Medline (January
1980 to September 2005) were used to search articles. Ab-
stracts presented between 2002 and 2005 at annual meetingsof the American Society of Haematology (ASH), the Inter-
science Conference on Antimicrobial Agents and Chemo-
therapy (ICAAC), the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID), the Ameri-
can Society of Clinical Oncology (ASCO) and the European
Bone Marrow Transplantation (EBMT) were also evaluated.
References of all included trials and reviews were also
checked. Databases were searched using the terms ‘neutro-
paenia’ or ‘agranulocytosis’ and similar; ‘anti-infective
agents’ (including antibacterial and antibiotics); ‘clinical
trial’ and similar; and ‘aminoglycosides’ or ‘gentamicin’,
‘kanamycin’, ‘amikacin’, ‘tobramycin’ and ‘netilmicin’. Selec-
tion of relevant articles and abstracts was performed inde-
pendently by two of the investigators (LD, FM and MP),
crosschecked and approved by members of the study group
(Fig. 1). Disagreements were resolved by consensus. All ran-
domised controlled trials comparing b-lactam antibiotic
monotherapy versus b-lactam–aminoglycoside combination
therapy in adult neutropaenic cancer patients with acute
leukaemia and meta-analyses comparing these regimens in
neutropaenic cancer patients were included in this review.
In addition, we included randomised controlled trials and
meta-analyses comparing once daily versus multiple daily
aminoglycoside dosing schedules in neutropaenic patients.
The quality of the evidence and levels of recommendations
were graded according to CDC criteria.9 The endpoints as-
sessed included all-cause mortality, treatment failure as de-
fined in the primary data source, adverse events and
infection-related mortality.3. Results
3.1. Questionnaire
The ECIL panel of experts (37 responders) preferred mono-
therapy for the initial, empirical treatment of febrile neutro-
paenia (71.2%) and they favour the use of piperacillin/
tazobactam (21%), meropenem (16%), imipenem (14.5%), cefe-
pime (13.2 %) and ceftazidime (7%). Less than one-third of
responders use b-lactam–aminoglycoside combinations for
empirical antibiotic therapy. Twenty-two respondents indi-
cated they would add an aminoglycoside for severe sepsis
(29%), suspected Pseudomonas infection or resistant Gram-
negative infection (26%), secondary infection (10%) and pneu-
monia (5%). The preferred aminoglycoside for the initial or
second-line therapy was amikacin (69%) followed by gentami-
cin (19%). The duration of aminoglycoside therapy was extre-
mely variable: ranging from 1 to 10–14 days or lasting until
recovery of neutropaenia.4. Review of the literature
4.1. b-Lactam monotherapy versus b-lactam–
aminoglycoside combination therapy
Seventy-five randomised controlled trials and two meta-anal-
yses comparing b-lactam monotherapy versus b-lactam–ami-
noglycoside combination therapy for febrile neutropaenia
were identified. The two meta-analyses, which included 66
Potentially relevant articles: 256
Not relevant: 549
Total articles retrieved: 805
Excluded: pharmacokinetic,
microbiological “in vitro” or
epidemiological studies: 103
Excluded: trials in which an
antibiotics combination (e.g
glycopeptides, quinolones,
cotrimoxazole) was evaluated
with or without an
aminoglycoside: 38
Excluded: other reasons: 32
75 randomised controlled trials comparing
beta-lactam monotherapy vs. beta-lactam-
aminoglycoside combination therapy for
high-risk febrile neutropenia included (66
assessed as part of existing meta-analyses)
8 randomised controlled trials comparing
once daily vs. thrice-daily aminoglycoside
treatment for febrile neutropenia included (4
assessed as part of existing meta-analyses)
Fig. 1 – Study flow chart.
E J C S U P P L E M E N T S 5 ( 2 0 0 7 ) 1 3 –2 2 15of the 75 trials identified, served as the main source of data
for the present review.10,11 The remaining nine trials were as-
sessed separately.12–20 Fifteen further studies, published
mainly as abstracts at international meeting, were also eval-
uated. However, they were not retained in the final analysis
for the following reasons: only children included,21–28 only so-
lid tumour patients included,29,30 non-randomised trials,31–34
no comparison between monotherapy and combination ther-
apy35 and one trial that included both neutropaenic and non-
neutropaenic patients.36
4.2. Meta-analysis 1
The first meta-analysis by Paul et al. was performed as a
Cochrane systematic review and published in 2002.10 Forty-
six randomised controlled trials (including 7642 patients)
comparing monotherapy with any b-lactam antibiotic to any
combination of a b-lactam and an aminoglycoside for the ini-
tial empirical treatment of febrile neutropaenic cancer pa-
tients were evaluated. The studies were performed between
1981 and 1999. The same b-lactam was used in both study
arms in only 9 trials and different b-lactam antibiotics were
used in the two study arms in 37 trials, consisting of a broad
spectrum b-lactam compared to a narrower-spectrum b-lac-
tam combined with an aminoglycoside. The b-lactams as-
sessed for monotherapy included ceftazidime (14 trials),
imipenem (14 trials, including a 2-armed trial), meropenem
(6 trials), moxalactam (4 trials), piperacillin/tazobactam (3 tri-als), cefepime (2 trials) and cefoperazone, ceftriaxone, lata-
moxef and piperacillin (one trial each). Neutropaenia was
defined as a neutrophil count of less than 0.5 · 109/L (500/
mm3) in half of the studies and less than 1.0 · 109/L (1000/
mm3) in the remainder. Bacteraemia was documented in
1874 patients. Microbiologically defined infections due to
Gram-negative bacilli accounted for 12% (4–59%) of all treat-
ment episodes and P. aeruginosa for less than 2% (0–13%) of
episodes.
The study endpoints were analysed overall and in six sub-
groups: patients with underlying haematological malignancy
or bone marrow transplantation, patients with an absolute
granulocyte count of less than 0.1 · 109/L (100/mm3), patients
with bacteraemia, patients with microbiologically or clinically
defined infections, patients with documented Gram-negative
infections and patients with documented Pseudomonas
infections.
The primary end-point was all-cause mortality defined as
death at the end of follow-up for the infectious episode, up
to 30 days. It was assessed in 29 studies. The average mortal-
ity rate was 6.2% (1.2–30%) with a mortality decline correlat-
ing with the year of the study. No significant difference
between monotherapy and combination therapy was de-
tected for all cause mortality (including in the six subgroups
analysed). The overall relative risk of death was 0.85 (95% con-
fidence interval 0.72–1.02) (favouring monotherapy, Table 1).
The same results were obtained when the analysis was per-
formed separately in the trials in which the same b-lactam
Table 1 – Summary of the main results of the two
meta-analyses comparing beta-lactam monotherapy to
b-lactam-aminoglycoside combination therapy for
empirical therapy of febrile neutropaenia
Paul et al. 10
47 trials, 7807
patients, 8803
febrile episodes
Furno et al. 11
29 trials,
4795 febrile
episodes
All cause mortality
•All studies RR 0.85 CI 0.72–1.02
•Studies using
same b-lactam
in both
treatment
arms
RR 0.73 CI 0.49–1.08
Infection-related mortality
•All studies RR 0.76 CI 0.59–0.98
•Studies using
same b-lactam
in both
treatment
arms
RR 0.72 CI 0.42–1.23
Treatment failure
•All studies RR 0.91 CI 0.85-0.99 OR 0.88 CI 0.78–0.99
•Studies using
same b-lactam
in both
treatment
arms
RR 1.12 CI 0.96-1.29
Bacteraemia RR 0.69 CI 0.39–1.22
for mortality
RR 0.91 CI 0.80–1.04
for failure
OR 0.70 CI 0.54–0.92
for failure
Superinfections RR 0.97 CI 0.82–1.14
(bacterial
superinfections)
RR 0.75 CI 0.51–1.09
(fungal superinfections)
Adverse eventsa RR 0.57 CI 0.36–0.91
Nephrotoxicity RR 0.42 CI 0.32–0.56
a Adverse events requiring discontinuation of antibiotic treat-
ment. Relative risks (RR) or odds ratios (OR) with 95% confidence
intervals (CI) for the comparison of b-lactam monotherapy versus
b-lactam-aminoglycoside combination therapy. Values <1 favour
monotherapy.
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(Table 1).
One of the secondary endpoints, treatment failure, was a
composite end-point of one or more of the following: death,
persistence of infection, recurrence or worsening of clinical
signs and symptoms of presenting infection, or any modifica-
tion of the initial empirical antibiotic treatment. There was no
difference between monotherapy and combination therapy
with respect to treatment failure in the nine studies (includ-
ing 2178 episodes of neutropaenia) in which the same b-lac-
tam antibiotic was used in both study arms (relative risk
1.12; 95% CI 0.96–1.29, Table 1), but hetereogeneity was noted
between this subset of clinical studies (P = 0.056). In contrast,
studies comparing different b-lactams provided pooled rela-tive-risk results favouring monotherapy (relative risk 0.86;
95% CI 0.80–0.93, Table 1) without heterogeneity. The same re-
sult was observed in the subgroups of patients with microbi-
ologically defined infections and those with haematological
malignancies. Infection related mortality was reported in 25
trials, including 5074 patients. Overall results significantly fa-
voured monotherapy (relative risk 0.76; 95% CI 0.59–0.98,
P = 0.03), with a similar relative risk for studies comparing
the same b-lactam and studies comparing different b-lactams
(Table 1).
The rate of bacterial superinfections was similar in both
groups. Fungal superinfections were more common in the
combination treatment group, but the difference did not
reach statistical significance. Adverse events occurred signif-
icantly less frequently in the monotherapy arm than in the
combination treatment arm, especially nephrotoxicity (rela-
tive risk 0.42; 95% CI 0.32–0.56), even in the four studies in
which once-daily dosing had been used (relative risk 0.20;
95% CI 0.04–0.90). Severe nephrotoxicity, as defined in the
studies, was also significantly higher for patients treated with
b-lactam–aminoglycoside combination therapy.
4.3. Meta-analysis 2
The second meta-analysis by Furno et al. was based on 29
randomised controlled trials comparing monotherapy to
combination treatment with an aminoglycoside. A total num-
ber of 4795 febrile episodes were analysed of which 1029 were
associated with bacteraemia.11 The primary outcome mea-
sure was treatment failure defined as an inadequate clinical
response, requiring modification of antibiotic therapy, or
resulting in death. In 20 studies, the odds ratios favoured
monotherapy and in 8 combination therapy. The pooled odds
ratio for clinical failure with monotherapy versus combina-
tion therapy was 0.88 (95% CI 0.78–0.99), thus favouring
monotherapy (Table 1). However, analysis of higher quality
studies and subgroup analyses of patients with severe neutro-
paenia did not show any significant difference between
monotherapy and combination treatment. Analyses of pa-
tients more than 14-year-olds and evaluation of bacteraemic
episodes showed marginally significant differences favouring
monotherapy.
4.4. Additional studies
Results of the nine trials that were not included in previous
meta-analyses are summarised in Table 2. All-cause mortality
was assessed in three trials; their combined results were sim-
ilar to those obtained in the previous meta-analysis (relative
risk 0.80; 95% CI 0.38–1.67). Treatment failure, defined most
commonly as lack of defervescence within 72 h or need for
antibiotic modification, was assessed in all trials; no signifi-
cant difference between monotherapy and combination ther-
apy was found in all but one trial comparing piperacillin-
tazobactam to ceftriaxone,18 where monotherapy was advan-
tageous. Other outcomes are detailed in Table 2. Overall, the
results were similar to those observed in the previous meta-
analyses.
In summary, the review of the literature shows
that monotherapy with a broad-spectrum b-lactam
Table 2 – Summary of the main results of randomised controlled trials not included in previous meta-analyses
Study No. of
episodes
Treatment Patients
with AL (%)
All-cause
mortality (n/N)
Infection-related
mortality (n/N)
Treatment
failure (%)
Failure with
bacteraemia (n/N)
Super-
infections (%)
Bilgir et al. 16 40 Imipenem versus Piperacillin/
tazobactam + amikacin
Haematological
malignancies
NR NR M: 35; NR NR
C: 40
Bru et al. 15 M: 46 Ticarcillin/clavulanate versus Allogeneic NR NR M: 17.1; M: 4/15; M: 6.5;
C: 54 Ticarcillin/clavulanate + amikacin stem cell Tx C: 15.5 C: 1/13 C: 13
Gaytan-Martinez
et al. 17
M: 63; Cefepime versus AL+NHL NR NR M: 14.2; NR NR
C: 54 ceftazidime + amikacin C: 12.9
Gorschluter et al. 18 M: 98; Piperacillin/tazobactam versus M: 85.7; M: 5/98; M: 4/98; M: 42.9; M: 14/24; NR
C: 85 Ceftriaxone + gentamicin C: 82.4 C: 8/85 C: 6/85 C: 64.7a C: 19/25
Kiel et al. 14 M: 35; Piperacillin/tazobactam versus All NR NR M: 40; NR NR
C: 35 Piperacillin/tazobactam + netilmicin C: 33
Kliasova et al. 13 M: 23 Meropenem versus Bone marrow M: 1/22; NR M: 35; NR NR
C: 20 Ceftazidime + amikacin Tx C: 2/20 C: 50
Miller et al. 19 M: 45; Imipenem versus NR NR NR M: 10; NR M: 18;
C: 41 Piperacillin + tobramicin C: 24 C: 7
Tamura et al. 20 M: 95; Cefepime versus M: 47.4; M: 7/95; NR M: 67.4; M: 3/4; NR
C: 94 Cefepime + amikacin C: 47.9 C: 5/94 C: 56.3 C: 4/7
Wrzesien-Kus et al. 12 M: 19 Cefepime versus NR NR NR M: 52.6; NR NR
C: 21 Cefepime + amikacin C: 47.6
M: monotherapy; C: combination therapy; NR: not reported; AL: acute leukaemia; NHL: non-Hodgkin’s lymphoma; Tx: transplantation.
a Significant advantage to monotherapy, P = 0.0047; no significant difference between monotherapy and combination therapy for all other comparisons.
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nephrotoxic) than combination therapy with a b-lactam
and an aminoglycoside.
4.5. Once daily versus multiple daily dosing of
aminoglycosides
Eight randomised controlled trials compared the efficacy and
safety of once versus thrice daily aminoglycoside therapy in
febrile neutropaenic patients.37–44 Four of these trials have
been evaluated in a previous meta-analysis.45 Clinical failure
and mortality rates were similar in patients treated with once
daily or thrice daily aminoglycosides (risk ratio 0.97; 95% CI
0.91–1.05 for clinical failure and 0.93; 95% CI 0.62–1.41 for mor-
tality). The pooled nephrotoxicity risk ratio was somewhat
lower in once-daily regimens than in multiple daily regimens
(0.78; 95% CI 0.31–1.94), but did not reach statistical signifi-
cance. Two additional studies compared single daily amikacin
with ceftriaxone versus thrice daily amikacin with ceftazi-
dime and showed similar efficacy and toxicity rates.38,39 Sung
et al. compared once versus thrice daily tobramycin com-
bined with either piperacillin or ceftazidime. A statistically
significant higher efficacy and a trend towards lower nephro-
toxicity were noted in the once-daily regimen.37 Torfoss et al.
compared tobramycin given once versus three times a day in
combination with penicillin for febrile patients with acute
leukaemia or lymphoma and severe neutropaenia.43 Efficacy
and toxicity rates were similar in the aminoglycoside treat-
ment groups.
In summary, the evidence gathered in several randomised
controlled trials indicates that once daily dosing of an amino-
glycoside is as efficacious as and probably less nephrotoxic
than multiple daily dosing among neutropaenic patients.
Similar results have been obtained in multiple randomised
trials and several meta-analyses conducted in non-neutro-
paenic patients.46–52
4.6. Recommendations for aminoglycosides in
international guidelines
Recent guidelines on the use of antimicrobial agents for the
management of febrile neutropaenia have also addressed
the issue of the use of aminoglycosides. In the guidelines of
the Infectious Diseases Society of America (2002), b-lactam
monotherapy (cefepime, ceftazidime, imipenem, meropenem
and possibly piperacillin-tazobactam) was considered equiva-
lent to combination therapy for empirical therapy of uncom-
plicated episodes of febrile neutropaenia.9 In the case of
progression of infection or development of a complication,
the guidelines suggested that consideration be given to addi-
tion of an appropriate antibiotic or a change to different anti-
biotics. There was no specific recommendation regarding
aminoglycoside-dosing schedule.
The guidelines of the Infectious Diseases Working Party of
the German Society of Haematology and Oncology (2003)
listed monotherapy (ceftazidime, cefepime, imipenem/cila-
statin, meropenem and piperacillin-tazobactam) and
combination therapy (acylaminopenicillin or third- or
fourth-generation cephalosporins plus an aminoglycoside)
as equivalent options for first-line treatment.53 In case ofpersistence of fever and neutropaenia 6–9 days after initial
antibiotic therapy, once or thrice-daily administration of ami-
kacin and netilmicin was recommended as a treatment op-
tion in patients at intermediate risk who had been initially
treated with monotherapy.
In the guidelines of the National Comprehensive Cancer
Network (2005), broad-spectrum monotherapy was consid-
ered comparable to b-lactam aminoglycoside combination
therapy. However, treatment with an anti-pseudomonal b-
lactam with an aminoglycoside was recommended as first
line therapy in clinically unstable patients (e.g. hypotension)
or in patients at high-risk for P. aeruginosa infection.54 The
guidelines also recommend that the addition of an aminogly-
coside to the initial antibiotic regimen be considered for pa-
tients with persistent fever, those who are clinically
unstable and for microbiologically defined P. aeruginosa infec-
tions. There was no recommendation for the use of once-dai-
ly dosing of aminoglycosides.5. Recommendations
The recommendations are summarised in Table 3 and are de-
tailed below.(1) Is b-lactammonotherapy as efficacious as a com-
bination of a b-lactam plus an aminoglycoside for
upfront empirical therapy in high-risk febrile
neutropaenic patients with acute leukaemia or
HSCT?
Answer: Yes, grading AI.
Comments: Available evidence shows that monotherapy
is at least as efficacious as b-lactam-aminoglycoside
combination therapy with regard to overall survival,
overall response defined as a resolution of fever or of
infection without modification of the initial antibiotic
regimen, response of documented Gram-negative
infections, and infection-related mortality. The mono-
therapies evaluated in these trials included ceftazi-
dime, cefepime, imipenem/cilastatin, meropenem
and piperacillin/tazobactam. Local advantages and
disadvantages to each of the monotherapies may
influence selection of the specific monotherapy. Ceft-
azidime may be inadequate in settings with high prev-
alence of extended spectrum b-lactamases producing
microorganisms and is less active against Gram-posi-
tive bacteria;55 imipenem has been associated with
increased rates of pseudomembranous colitis;56,57
piperacillin-tazobactam is associated with false-posi-
tive galactomannan assays;58 and cefepime was asso-
ciated with higher all-cause mortality when
compared to other monotherapies in randomised tri-
als.56 Thus, the appropriate b-lactam for monotherapy
should be selected according to local epidemiology,
antibiotic resistance patterns, recent b-lactam use
and available evidence.
(2) Is a combination of a b-lactam plus an aminogly-
coside more nephrotoxic or ototoxic than b-lac-
tam monotherapy?
Answer: Yes, grading AI for both nephrotoxicity and
ototoxicity.
Table 3 – Summary of recommendations
Problem Recommendation Gradinga
BL monotherapy is as efficacious as BL + AG as empirical therapy of febrile neutropaenia Yes A I
BL + AG combination is more nephrotoxic and ototoxic than BL monotherapy Yes A I
OD dosing of AG are as efficacious as and less nephrotoxic than MDD Yes A I
Empirical addition of AG to the initial regimen in patients with persistent fever No C III
Empirical use of BL + AG combination in patients in whom a resistant Gram-negative infectionb is suspected Yes C III
Addition of AG to the initial regimen in case of documented P. aeruginosa infection No C III
Use of BL + AG combination in patients with severe sepsis or septic shock Yes C III
Use of BL + AG in neutropaenic patients with pneumonia No C III
Use of BL + AG combination to prevent emergence of resistance during therapy No B I
BL: b-lactam; AG: aminoglycoside; OD: once-daily dosing; MDD: multiple-daily dosing.
a Level of evidence and level of recommendation.9
b Local epidemiology and previous antibiotic treatments should be taken into account.
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trials comparing monotherapy with combination
therapy. Amikacin, netilmicin, gentamicin and tobra-
mycin were the aminoglycosides used in these trials.
Nephrotoxicity and severe nephrotoxicity occurred
significantly more often among patients treated with
combination therapy than in those treated with
monotherapy. The number needed to prevent one
episode of nephrotoxicity when using b-lactam
monotherapy was 31.10 Among 14 trials reporting
ototoxicity, 19 patients developed ototoxicity in the
combination treatment arm versus three patients in
the monotherapy arm (unpublished data from Paul
et al.10). Routine monitoring for ototoxicity with
audiometry was rarely performed in these studies.
(3) Is there evidence that once-daily administration
of aminoglycosides is as efficacious as and poten-
tially less toxic than multiple-dose administra-
tion for febrile neutropaenic patients?
Answer: Yes, grading AI.
Comments: Results from several randomised controlled
trials suggest that survival rates and efficacy (as
assessed by successful treatment without the need for
modification of antibiotic therapy) are similar for
high-risk neutropaenic patients treated with either
once daily or multiple dose administration of aminogly-
cosides. Moreover, nephrotoxicity was less frequent
among patients treated with once-daily dosing.
(4) Is there evidence supporting the empirical addi-
tion of an aminoglycoside to patients initially
treated with monotherapy with persistent fever?
Answer: No, grading CIII.
Comments: We are not aware of clinical trials that have
addressedthatquestionforpatientswithpersistent fever.
(5) Are there specific clinical conditions justifying
the use of an aminoglycoside as part of the
empirical antibiotic regimen? Specific clinical
conditions for which the use of an aminoglyco-
side might be considered include a high suspi-
cion or microbiological documentation of aninfection caused by P. aeruginosa or resistant
Gram-negative bacilli, pneumonia and the occur-
rence of life-threatening conditions, such as
severe sepsis or septic shock. We will consider
each of these possible indications below.(a) Suspicion of infections caused by resistant
P. aeruginosa or other resistant Gram-nega-
tive bacteria.
Answer: Yes, grading CIII.
Comments: There are no data to support the empiri-
cal use of a combination of an aminoglycoside and
a b-lactam antibiotic for treating infections sus-
pected to be due to resistant Gram-negative bacilli
(including P. aeruginosa). However, given the risk of
poor outcome in neutropaenic patients treated with
inappropriate antibiotics, especially in centres
where resistant Gram-negative bacteria are a con-
cern, we recommend using a combination therapy
as empirical regimen until microbiological data
become available. The aminoglycoside should be
discontinued as soon as resistance to the b-lactam
antibiotic has been ruled out.
(b) Documented Pseudomonas aeruginosa
infections
Answer: No, grading CIII.
Comments: In the meta-analysis by Paul et al. no sig-
nificant differences were observed between mono-
therapy and combination therapy with respect to
the subgroup of patientswith documented P. aerugin-
osa infections.10 Only 58 patients were assessed for
mortality and 139 patients for treatment failure. In a
meta-analysis including non-neutropaenic patients,
a significant survival benefit for combination therapy
was found in the subgroup of patientswith P. aerugin-
osa bacteraemia.59 However, this meta-analysis
included observational studies, a heterogenous
patient population and single aminoglycoside treat-
ment in the monotherapy arm, precluding firm
conclusion regarding b-lactam monotherapy. Thus,
there is no proven advantage of adding an
20 E J C S U P P L E M E N T S 5 ( 2 0 0 7 ) 1 3 –2 2aminoglycoside to a b-lactam antibiotic when the P.
aeruginosa is fully susceptible to the b-lactam agent.
In fact, susceptibility of gram-negative bacilli to the
b-lactamused is aprimarydeterminantofoutcome.60
(c) Severe sepsis and septic shock.
Answer: Yes, grading CIII.
Comments: Severe sepsis and septic shock occur in
only 1–2% of febrile neutropaenic episodes.61,62 How-
ever, given that patients with septic shock often are
excluded from many clinical studies, the incidence
of these complications might be underestimated. In
a logistic regression analysis of patient’s outcome
performed in 909 neutropaenic cancer patients with
bacteraemia, the risk of death was significantly
increased in hypotensive patients.63 Although no
data are available, it is recommended to use an ami-
noglycoside antibiotic in febrile neutropaenic
patients with severe sepsis or septic shock.
(d) Pneumonia.
Answer: No, grading CIII.
(6) Does the use of b-lactam-aminoglycoside
combinations in neutropaenic patients pre-
vent the emergence of resistant bacteria?
Answer: No, grading BI.
Comments: Current evidence indicates that b-lactam
monotherapy is not associated with an increased
risk of emergence of resistant bacteria when com-
pared with b-lactam and aminoglycoside combina-
tions. Paul et al. assessed bacterial superinfections
as a surrogate marker of induction of resistance.
No difference was found between combination and
monotherapy.10 Only two studies compared the fre-
quency of colonisation with resistant Gram-negative
bacteria after treatment, which occurred in 5 of 152
patients (3%) treated with monotherapy and in 1 of
152 patients (0.6%) treated with a combination of
antibiotics.64,65 Bliziotis et al. conducted a meta-
analysis of randomised controlled trials aimed at
comparing the effect of combinations of an amino-
glycoside and a b-lactam antibiotic and of b-lactam
monotherapy on the emergence of antimicrobial
resistance among non-neutropaenic patients.66
Beta-lactam monotherapy was associated with
fewer superinfections, while treatment failure
attributable to resistance induction or superinfec-
tions did not differ significantly between the two
study arms. Thus, data from randomised trials do
not suggest that the use of an aminoglycoside-
containing antibiotic regimen is associated with
a reduced risk of the emergence of resistant
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